Eldecalcitol replaces endogenous calcitriol but does not fully compensate for its action in vivo  by Saito, Hitoshi & Harada, Suguru
OE
c
H
M
a
A
R
R
1
A
A
K
E
V
C
P
C
a
T
0
hJournal of Steroid Biochemistry & Molecular Biology 144 (2014) 189–196
Contents lists available at ScienceDirect
Journal  of  Steroid  Biochemistry  and  Molecular  Biology
j ourna l h omepage: www.elsev ier .com/ locate / j sbmb
riginal  Article
ldecalcitol  replaces  endogenous  calcitriol  but  does  not  fully
ompensate  for  its  action  in  vivo
itoshi  Saito ∗,1,  Suguru  Harada1
edical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 1 August 2013
eceived in revised form
7 November 2013
ccepted 19 November 2013
vailable online 26 November 2013
eywords:
ldecalcitol
DR
alcium
hosphorus
a  b  s  t  r  a  c  t
Calcitriol  (1,25-dihydroxyvitamin  D3, 1,25(OH)2D3) is an  essential  hormone  that  works  in cooper-
ation  with parathyroid  hormone  (PTH)  and  ﬁbroblast  growth  factor-23  (FGF-23)  to  regulate  calcium
and  phosphorus  homeostasis.  Previous  in  vivo studies  in  rats  have  shown  that  eldecalcitol,  a  vitamin  D
analog,  is  more  active  than  calcitriol  in stimulating  calcium  and  phosphorus  absorption  in the  intestine
and  in  increasing  serum  FGF-23,  but is  not  as  active  in suppressing  blood  PTH.  However,  those  results
are  problematic  because  administration  of  exogenous  eldecalcitol  or calcitriol  affects  the  synthesis  and
degradation  of  endogenous  calcitriol,  and  competes  for binding  to vitamin  D  receptor  (VDR)  in  target  tis-
sues. Therefore,  we  tried  to evaluate  the  ‘true  biological  activity  in  vivo’  of each  compound  by comparing
their  biological  activities  with  respect  to  their blood  concentrations.
In VDR  gene  knockout  mice,  calcitriol  and  eldecalcitol  did not  affect  either  serum  or urinary  calcium
levels,  and also  did  not  induce  the  expression  of target  genes.  These  results  indicate  that  the actions  of
eldecalcitol  are  mediated  by VDR.  In normal  rats,  concentrations  of both  calcitriol  and  eldecalcitol  in
the blood  increased  dose-dependently  and  had  a linear  correlation  with  administered  dosage.  The con-
centration  of  calcitriol  in  the blood  was  reduced  by  eldecalcitol  treatment,  falling  to below  the  limit of
detection  at  0.1  g/kg  eldecalcitol.  Based  on  the  concentration  of each  compound  in the blood,  eldecalci-
tol  had approximately  1/4  to 1/7  the activity  of  calcitriol  to increase  serum  calcium,  FGF-23,  and  urinary
calcium  excretion,  and  to  suppress  blood  PTH. Eldecalcitol  dose-dependently  increased  urinary  phos-
phorus  excretion  and  reduced  serum  phosphorus.  However,  calcitriol  did  not  change  serum  phosphorus.
In accordance  with  serum  chemistry  and  hormones,  a concentration  of eldecalcitol  in  the  blood  of 3–8
times  that  of  calcitriol  was  required  to stimulate  target  gene  expressions  in  the  kidneys  (VDR,  TRPV5,
and  calbindin-D28k)  and  bone  (VDR,  FGF-23,  and  RANKL).  On the  other  hand,  the blood  concentrations
of  eldecalcitol  needed  to stimulate  target  genes  in  the  intestine  (TRPV6,  calbindin-D9k,  and  VDR)  were
comparable  to those  of  calcitriol.  These  results  indicate  that oral  administration  of eldecalcitol  stimulates
target  gene  expression  in the  intestine  similarly  to calcitriol,  but to  a much  lesser  extent  than  calcitriol  in
the  kidneys  and  bones.  The  major  ﬁnding  of the  present  study  is  that eldecalcitol  suppresses  endogenous
calcitriol  and  replaces  it.  However,  it may  not  fully  compensate  for the  action  of calcitriol  in  vivo.This article  is  part  of a Special  Issue  entitled  ‘16th  Vitamin  D  Workshop’.
© 2013  The  Author.  Published  by Elsevier  Ltd.  All rights  reserved.
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. Introduction
Calcitriol (1,25-dihydroxyvitamin D3, 1,25(OH)2D3) exerts
 wide variety of biological actions in many target organs. Cal-
itriol regulates calcium and phosphorus homeostasis, mineral
etabolism, and bone metabolism. Through the action of calcitriol,
n cooperation with parathyroid hormone (PTH) and ﬁbroblast
rowth factor-23 (FGF-23), the absorption of intestinal calcium and
hosphorus, resorption of bone phosphorus and calcium, and reab-
orption of renal calcium and phosphorus are increased, resulting
n a rise in the serum calcium and phosphorus available for bone
ineralization [1–3].
Vitamin D3 is ﬁrst metabolized to 25-hydroxyvitamin D3
25(OH)D3] in the liver, then to calcitriol (1,25(OH)2D3) in the
idneys. In this pathway, renal 1-hydroxylation (by 25-OHD-1-
ydroxylase, CYP27B1) is a rate-limiting step in the production of
alcitriol. Degradation of 25(OH)D3 and calcitriol is mediated by
enal 24-hydroxylase (CYP24A1). The concentration of calcitriol in
he blood is tightly regulated by a feedback loop controlling expres-
ion of renal CYP27B1 and CYP24A1. Expression of these enzymes
s strictly regulated by PTH, FGF-23, and the vitamin D status of
nimals [3–7].
The biological actions of calcitriol are mediated through vitamin
 receptor (VDR). VDR is a member of the nuclear hormone receptor
ene family and is a ligand-dependent transcription factor [8–10].
he physiological importance of VDR in maintaining the integrity
f mineral metabolism is indicated by the observation that patients
ith vitamin D deﬁciency and VDR gene knockout (VDRKO) mice
oth develop hypocalcemia and rickets or osteomalacia [11–13].
The intestinal and renal transepithelial transport of calcium
n response to calcitriol is mediated by apical calcium ion chan-
els of the transient receptor potential vanilloid subfamily 5 and
 (TRPV5 and TRPV6), followed by cytosolic transport by calcium
inding proteins (calbindin-D9k and calbindin-D28k) and extru-
ion across the basolateral membrane into the extracellular ﬂuid
y plasma membrane calcium ATPase (PMCA1b) and/or sodium-
alcium exchanger (NCX1) [14].
Eldecalcitol (1,25-dihydroxy-2-(3-hydroxypropyloxy) vita-
in  D3), a new active vitamin D3 analog, has recently been
pproved for the treatment of osteoporosis in Japan. A Phase III
linical trial in patients with osteoporosis showed that eldecalcitol
ncreased bone mineral density (BMD) and reduced the incidence
f vertebral fracture with an efﬁcacy greater than that of alfacalci-
ol [15]. It has also been shown that eldecalcitol promotes urinary
alcium excretion similarly to alfacalcidol, but has a lower potency
o suppress blood PTH [16]. Eldecalcitol increases BMD  and reduces
one turnover markers in normal, ovariectomized (OVX), and
teroid-treated rats, and also in patients with osteoporosis [17–21].
ldecalcitol is more active than calcitriol in stimulating calcium
nd phosphorus absorption in the intestine, as well as in increas-
ng serum FGF-23 in normal rats [22]. However, administration
f exogenous eldecalcitol or calcitriol affects the synthesis and/or
egradation of endogenous calcitriol, and exogenous eldecalcitol or . . . . .  . . .  . .  . . .  . .  . . .  . . . . .  . .  . . . . . . .  .  . . . . . . .  . . . . . .  .  . . . .  . . . . .  .  . . .  .  .  .  . . . . . . . . . .  196
calcitriol competes with endogenous calcitriol for binding to VDR
in target tissues. In the current study, we tried to evaluate the ‘true
biological activity in vivo’ of each compound by comparing their
biological activities with respect to their blood concentrations.
2. Materials and methods
2.1. Chemicals
Calcitriol was  purchased from Wako Pure Chemical Industries
(Osaka, Japan). Eldecalcitol was  synthesized by Chugai Pharmaceu-
tical Co., Ltd. (Tokyo, Japan).
2.2. Animals
2.2.1. Experiment 1
VDRKO mice were kindly provided by Dr. S. Kato [11]. VDRKO
mice were fed ad libitum with a rescue diet containing 2% calcium,
1.25% phosphorus, and 20% lactose (CLEA Japan, Tokyo, Japan) [23];
wild-type (WT) mice were fed normal rodent chow (CE-2; CLEA
Japan). All animals were given free access to tap water and were
maintained under speciﬁc pathogen free conditions with a 12-h
light and dark cycle at 20–26 ◦C and humidity of 35–75%. The 9-
week-old VDRKO and WT  mice were divided into 3 groups based
on body weight. Mice were administered either a vehicle control
(medium chain triglyceride; The Nisshin Oillio Group, Tokyo, Japan)
(MCT), eldecalcitol (0.2 g/kg), or calcitriol (2 g/kg) by once-a-day
oral gavage for 14 days (n = 5). Blood, kidney, and intestine samples
were collected 6 h after the last dosing.
2.2.2. Experiment 2
Six-week-old male Sprague-Dawley rats were purchased from
CLEA Japan. Animals were fed with normal rodent chow and tap
water and acclimated to the above conditions for 1 week. Rats were
divided into 11 groups based on body weight. Various doses of elde-
calcitol (0.025, 0.05, 0.1, 0.25, and 0.5 g/kg), calcitriol (0.25, 0.5,
1, 2.5, and 5 g/kg), or MCT  vehicle were administered by once-
a-day oral gavage for 14 days (n = 6). On the 13th day, rats were
transferred to and kept in metabolic cages for 24 h to collect urine
samples. Blood, bone, kidney, and intestine samples were collected
at 6 h after the last dosing on the 14th day.
Both animal studies were carried out in accordance with Chugai
Pharmaceutical’s ethical guidelines of animal care, and the experi-
mental protocols were approved by the animal care committee of
the institution.
2.3. Biochemical analysis
Levels of calcium, phosphorus, and creatinine in serum and urine
were determined by using an automatic analyzer (TBA-120FR;
Toshiba Medical Systems, Tochigi, Japan). PTH in plasma was mea-
sured by rat intact PTH ELISA kit (Immutopics International, San
Clemente, CA, USA). FGF-23 in serum was measured by FGF-23
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A),  urinary calcium excretion (B), TRPV5 (C) and calbindin-D28k (D) mRNA express
re  shown. Values represent means + SE (n = 5 for each treatment group). (a) p < 0.05
LISA kit (Kainos Laboratories, Tokyo, Japan). Calcitriol in serum
as measured by 1,25(OH)2D RIA kit (TFB, Tokyo, Japan). Measure-
ent of eldecalcitol in plasma was performed at the BoZo Research
enter (Tokyo, Japan).
.4. Quantitative RT-PCRThe right femur, intestine, and kidneys of mice, and the right
emur, intestine, and kidneys of rats were excised and immedi-
tely frozen in liquid nitrogen. A small portion of each of the frozen
issues was soaked in TRIzol (Invitrogen, Carlsbad, CA, USA) andd kidney samples were recovered for further analyses. Serum calcium concentration
 the kidney, and TRPV6 (E) and calbindin-D9k (F) mRNA expression in the intestine
pared with the vehicle control group, using Tukey’s multiple test.)
crushed in a homogenizer (Physcotron NS-310E; Microtec, Chiba,
Japan). Total RNA was extracted with an RNeasy Mini Kit (Qiagen,
Hilden, Germany). cDNA was  synthesized from 200 ng of total RNA
by reverse transcription PCR using TaqMan Reverse Transcription
Reagents (Applied Biosystems, Foster City, CA, USA). The reaction
was performed at 37 ◦C for 1 h. Expression of mRNA in the tis-
sues was detected using TaqMan Gene Expression Assays (Applied
Biosystems). Target cDNA was ampliﬁed by 40 cycles (1 cycle: 95 ◦C
for 15 s, 60 ◦C for 1 min) of PCR in an ABI PRISM 7000 Sequence
Detector System (Applied Biosystems). The TaqMan probes used in
this study were TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k
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c  of cal
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c
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a
Ioncentration of eldecalcitol in the eldecalcitol-treated rats (A), serum concentration
n  the eldecalcitol-treated rats (C), and renal mRNA expression of CYP27B1 (D) and 
 < 0.05 (Compared with the normal control group using Dunnett’s multiple test.)
f mice and TRPV5, TRPV6, calbindin-D28k, calbindin-D9k, recep-
or activator of NF-B ligand (RANKL), FGF-23, CYP27B1, CYP24A1,
nd VDR of rats. 18S rRNA was used as a control. Data are repre-
ented as expression relative to that in rats treated with vehicle
ontrol.
.5. Statistical analysisData are presented as mean ± standard error (SE). Statistical
nalysis was performed using the SAS System for Windows (SAS
nstitute, Cary, NC, USA). Statistical signiﬁcance was  determinedcitriol in the calcitriol-treated rats (B), serum concentration of endogenous calcitriol
A1 (E) are shown. Values represent means ± SE (n = 6 for each treatment group). (a)
by Tukey’s test in Section 2.2.1, and by Dunnett’s test in Section
2.2.2.
3. Results
3.1. Effects of eldecalcitol on calcium metabolism in VDRKO miceA dose of 2 g/kg calcitriol or 0.2 g/kg eldecalcitol admin-
istered daily by oral gavage for 14 days signiﬁcantly increased
serum calcium and urinary calcium excretion compared with vehi-
cle administration in WT mice. However, neither eldecalcitol nor
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(alcium excretion (D), serum FGF-23 (E), and plasma PTH (F) are shown. Values repr
ontrol group using Dunnett’s multiple test.)
alcitriol affected serum or urinary calcium in the VDRKO mice
Fig. 1A and B). Calcitriol and eldecalcitol signiﬁcantly increased
he expression of renal TRPV5 and calbindin-D28k mRNA and the
xpression of intestinal TRPV6 and calbindin-D9k mRNA in the WT
ice. On the other hand, the expression of these genes in the VDRKO
ice was not altered by the treatment (Fig. 1C–F). These results
ndicate that the calcemic actions of calcitriol and eldecalcitol are
ediated by VDR.
.2. Effects of eldecalcitol on calcium and phosphorus metabolism
n normal rats
Eldecalcitol (0.025, 0.05, 0.1, 0.25, and 0.5 g/kg) or cal-
itriol (0.25, 0.5, 1, 2.5, and 5 g/kg) administered daily by oral
avage for 14 days dose-dependently increased the blood con-
entration of each compound. The blood concentration of each
ompound correlated well with the administered dosage (eldecal-
itol: y (pmol/L) = 29,834x (g/kg) + 646.3, R2 = 0.996; calcitriol: y
pmol/L) = 681.81x (g/kg) + 402.1, R2 = 0.971) (Fig. 2A and B). Thiseans ± SE (n = 6 for each treatment group). (a) p < 0.05 (Compared with the normal
result indicates that in order to reach the same concentration in the
blood, the amount of eldecalcitol required is approximately 1/40
that of calcitriol. In the eldecalcitol-treated rats, serum concentra-
tion of calcitriol dose-dependently decreased and fell to below the
limit of detection at 0.1 g/kg (Fig. 2C). Treatment with eldecalcitol
and calcitriol signiﬁcantly reduced renal CYP27B1 gene expression
and dose-dependently increased renal CYP24A1 gene expression
(Fig. 2D and E). These results suggest that the administration of
eldecalcitol and calcitriol reduces endogenous production of cal-
citriol and stimulates degradation of calcitriol in the kidneys.
Blood concentrations of eldecalcitol and calcitriol correlated
with urinary phosphorus excretion. Serum phosphorus slightly
decreased along with the increase in eldecalcitol concentration in
blood, whereas calcitriol concentration did not alter serum phos-
phorus (Fig. 3A and B). Serum calcium was  signiﬁcantly elevated
at higher blood concentrations of eldecalcitol (≥7520 pmol/L) and
calcitriol (≥1170 pmol/L) (Fig. 3C). Urinary calcium excretion cor-
related with blood concentrations of calcitriol and eldecalcitol
(Fig. 3D). Serum FGF-23 increased at 15,800 pmol/L of eldecalcitol
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nd at ≥2480 pmol/L of calcitriol in blood (Fig. 3E). High concen-
rations of eldecalcitol in the blood (≥7520 pmol/L) suppressed
lasma PTH concentration, whereas plasma PTH concentration was
educed from low blood calcitriol concentrations (≥590 pmol/L)
Fig. 3F).
.3. Effects of eldecalcitol on target gene expression in normal rats
In the intestine, TRPV6 gene expression was induced from rel-
tively low blood concentrations of eldecalcitol (≥1220 pmol/L)
Fig. 4A). Similarly, induction of TRPV6 gene expression was
bserved from low concentrations of calcitriol (590 pmol/L and
2480 pmol/L). Calbindin-D9k gene expression was unchanged by
he administration of calcitriol or eldecalcitol (Fig. 4B). In the kid-
eys, TRPV5 mRNA expression was signiﬁcantly elevated at the
ighest concentration of eldecalcitol (15,800 pmol/L) and at high
oncentrations of calcitriol (≥1170 pmol/L) (Fig. 4C). Calbindin-
28k mRNA was  increased at the higher blood concentrations ofeldecalcitol (≥7520 pmol/L) and calcitriol (≥1170 pmol/L) (Fig. 4D).
In bone, blood concentrations of calcitriol correlated with RANKL
and FGF-23 gene expression; however, only the highest concen-
tration of eldecalcitol (15,800 pmol/L) induced RANKL and FGF-23
gene expression (Fig. 4E).
Blood concentration of calcitriol correlated with VDR gene
expression in the kidneys and bone (Fig. 5B and C), but calcitriol did
not affect VDR gene expression in the intestine (Fig. 5A). Induction
of VDR gene expression in the intestine and kidneys were asso-
ciated with increasing concentration of eldecalcitol in the blood
(Fig. 5A and B). In bone, signiﬁcant induction of VDR gene expres-
sion was observed only at the highest concentration of eldecalcitol
(Fig. 5C).
Taken together, these results show that, in comparison to cal-
citriol, relatively higher concentrations of eldecalcitol in the blood
were required to stimulate expression of vitamin D target genes
in the kidneys (VDR, TRPV5, and calbindin-D28k) and bone (VDR,
RANKL, and FGF-23).
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ral  gavage. Intestine, kidney, and bone samples were recovered for further analys
alues  represent means ± SE (n = 6 for each treatment group). (a) p < 0.05 (Compare
.4. Comparison of the ‘true in vivo biological activity’ of
ldecalcitol and calcitriol
In order to compare the true biological activity of calcitriol and
ldecalcitol in vivo, the blood concentration required to elicit a 50%
esponse in each activity was calculated from the raw data above.
he ratio of biological activity was obtained by dividing the 50%
esponse concentration of calcitriol by that of eldecalcitol. Based
n these calculations, eldecalcitol was approximately 1/4 to 1/7
s active as calcitriol in increasing serum calcium and FGF-23, in
timulating urinary calcium excretion, and in suppressing plasma
TH (Table 1). Eldecalcitol was approximately 1/3 to 1/8 as active
s calcitriol in stimulating expression of target genes in the kid-
eys (VDR, TRPV5, and calbindin-D28k) and bone (VDR, FGF-23,
nd RANKL). The biological activities of eldecalcitol in increasing
able 1
elative biological activity of eldecalcitol compared to that of calcitriol.
Blood concentration required for
Eldecalcitol 
Biochemical parameters
Serum calcium 8841 
Urinary calcium excretion 4856 
Serum  FGF-23 11,232 
Plasma PTH 3876 
Target  gene
Bone
VDR 10,791 
FGF-23 11,506 
RANKL  10,711 
Kidney
VDR  6711 
TRPV5  11,033 
Calbindin-D28k 6768 eek-old male rats were administered either eldecalcitol or calcitriol for 14 days by
NA expressions of intestinal VDR (A), renal VDR (B), and bone VDR (C) are shown.
 the normal control group using Dunnett’s multiple test.)
intestinal TRPV6 and VDR gene expression were comparable to
those of calcitriol (Figs. 4A and 5A).
4. Discussion
The half-life of eldecalcitol in the blood is much longer than
it is for calcitriol [23]. Although eldecalcitol strongly induces
CYP24A1 in the intestine and kidneys [24], eldecalcitol itself is
hardly degraded by CYP24A1 [25]. At the same time, eldecalcitol
strongly suppresses CYP27B1 in the kidneys. Blood concentration
of eldecalcitol during treatment in clinical trials was  reported to
be relatively high (200–250 pg/mL) in comparison to the normal
range of calcitriol (30–60 pg/mL) in humans [15]. An approximately
50% reduction in blood calcitriol was  observed during eldecalcitol
treatment in the clinical trial.
 a 50% response (pmol/L) Relative activity
Calcitriol
1288 0.15
1096 0.23
1779 0.16
563.7 0.15
1328 0.12
1668 0.14
1753 0.16
917 0.14
1850 0.17
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resistance to metabolism, J. Cell Biochem. 112 (2011) 1348–1352.96 H. Saito, S. Harada / Journal of Steroid Bioch
In the present study, we demonstrated by using VDRKO mice
hat the calcemic actions of calcitriol and eldecalcitol were medi-
ted solely by VDR. Administration of small amounts of eldecalcitol
n rats markedly reduced serum concentration of calcitriol, which
ell to below the limit of detection at 0.1 g/kg eldecalcitol.
lasma concentration of eldecalcitol increased dose-dependently
nd reached 3820 pmol/L by 0.1 g/kg eldecalcitol administration.
hese observations indicate that, after administration of eldecalci-
ol, the eldecalcitol rapidly replaces calcitriol in blood and exerts
iological activities in target organs. It was observed in an earlier
tudy that the binding activity of eldecalcitol to VDR is approxi-
ately 1/8 of that of calcitriol in vitro [26] and that the distribution
apacity of eldecalcitol to target organs is much lower than that of
alcitriol in rats.
In this study, based on the concentration of each compound in
he blood, the relative biological activities of eldecalcitol, such as its
ctivity in increasing serum calcium, FGF-23, and urinary calcium
xcretion, and in suppressing plasma PTH in vivo were only 15–26%
f that of calcitriol (Table 1). Eldecalcitol stimulated the expression
f target genes in the kidneys (VDR, TRPV5, and calbindin-D28k)
nd bone (VDR, FGF-23, and RANKL) much less than did calcitriol.
timulation of target genes in the intestine by eldecalcitol treat-
ent was comparable to that of calcitriol. These results indicate
hat eldecalcitol is primarily a weak agonist of VDR as compared
ith calcitriol in vivo.
Thus, we conclude that administration of eldecalcitol rapidly
uppresses endogenous calcitriol and replaces it. However, elde-
alcitol may  not fully compensate for the action of calcitriol in the
idneys and bone.
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